EVP Endocrine Business Unit Alejandro Galindo resigns effective Oct 21, 2022

MANNKIND CORP

Alejandro Galindo, Executive Vice President – Endocrine Business Unit, resigns to pursue other opportunity.
Resignation effective at close of business on October 21, 2022.
No replacement named or additional details provided in the filing.

item 8.01

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0001564590-22-032286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.